Dr. Blackwell is Vice-President, Early Phase Oncology and Immuno-Oncology at Eli Lilly Corporation, and Adjunct Professor of Medicine, Duke University Medical Center. One of the nation’s leading breast cancer researchers, Dr. Blackwell has played a major role in developing therapies that represent revolutionary non-chemotherapy based approaches for treating breast cancer. This work led to Dr Blackwell’s inclusion on TIME magazine’s 2013 list of the 100 most influential people in the world. Her work contributed to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. Her recent research interests include triple negative breast cancer and cancer that has spread to the brain. Dr Blackwell has served as the principal or co-principal investigator for over 50 cancer clinical trials, including two registration studies for biosimilar G-CSF. After 24 years at Duke Cancer Institute, she transitioned to the role of Vice President of Early Phase Oncology and Immuno-oncology at Eli Lilly where she oversees the clinical development teams for promising early stage therapeutics.